Membranous Nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults and the disease course is characterised by the "rule of third", with one third of patients experiencing complete remission and the remaining experiencing relapses or progression of the disease. Additionally, the therapeutic approach is not standardised, leading to further heterogeneity in terms of response and outcome. In this pilot study, MALDI-MSI analysis was performed on renal biopsies (n = 13) obtained from two homogeneous groups of patients which differentially responded to the immunosuppressive treatments (Ponticelli regimen). A signal at m/z 1303 displayed the greatest discriminatory power when comparing the two groups and was observed to be of higher intensity in the glomeruli of the non-responding patients. The corresponding tryptic peptide was identified as macrophage migration inhibitory factor (MIF). Despite much effort being made in recent years to understand the pathogenesis of MN, a biomarker able to predict the outcome of these patients following therapeutic treatment is still lacking. Here, we highlight a protein (MIF), verified by immunohistochemistry, which can differentiate between these MN patients and could be a valuable starting point for a further study focused on verifying its predictive role in therapy response. This article is protected by copyright. All rights reserved

L'Imperio, V., Smith, A., Ajello, E., Piga, I., Stella, M., Denti, V., et al. (2019). MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy. PROTEOMICS. CLINICAL APPLICATIONS, 13(3) [10.1002/prca.201800019].

MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy

L'Imperio V;Smith A;Ajello E;Piga I;Stella M;Denti V;Tettamanti S;Sinico RA;Pieruzzi F;Pagni F;Magni F.
2019

Abstract

Membranous Nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults and the disease course is characterised by the "rule of third", with one third of patients experiencing complete remission and the remaining experiencing relapses or progression of the disease. Additionally, the therapeutic approach is not standardised, leading to further heterogeneity in terms of response and outcome. In this pilot study, MALDI-MSI analysis was performed on renal biopsies (n = 13) obtained from two homogeneous groups of patients which differentially responded to the immunosuppressive treatments (Ponticelli regimen). A signal at m/z 1303 displayed the greatest discriminatory power when comparing the two groups and was observed to be of higher intensity in the glomeruli of the non-responding patients. The corresponding tryptic peptide was identified as macrophage migration inhibitory factor (MIF). Despite much effort being made in recent years to understand the pathogenesis of MN, a biomarker able to predict the outcome of these patients following therapeutic treatment is still lacking. Here, we highlight a protein (MIF), verified by immunohistochemistry, which can differentiate between these MN patients and could be a valuable starting point for a further study focused on verifying its predictive role in therapy response. This article is protected by copyright. All rights reserved
Articolo in rivista - Articolo scientifico
MALDI-MSI; macrophage migration inhibitory factor; mass spectrometry; membranous nephropathy; proteomics
English
L'Imperio, V., Smith, A., Ajello, E., Piga, I., Stella, M., Denti, V., et al. (2019). MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy. PROTEOMICS. CLINICAL APPLICATIONS, 13(3) [10.1002/prca.201800019].
L'Imperio, V; Smith, A; Ajello, E; Piga, I; Stella, M; Denti, V; Tettamanti, S; Sinico, R; Pieruzzi, F; Garozzo, M; Vischini, G; Nebuloni, M; Pagni, F; Magni, F
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/209229
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
Social impact